Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAROQUE: Otilimab + MTX in RA
NCT02504671Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2015
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of otilimab in rheumatoid arthritis (RA) (6 arms), sponsored by GSK. Primary endpoint: Percentage of Participants Who Achieved Disease Activity Score for 28 Different Joints With C-reactive Protein Value (DAS28{CRP}) Remission (DAS28 <2.6) at 24 weeks. Started Jul 2015; status: completed.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02504671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504671.